Dextrose And Sodium Chloride

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Dextrose And Sodium Chloride
Generic name
DEXTROSE AND SODIUM CHLORIDE
Manufacturer
B. Braun Medical Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
8e6569ce-9714-497f-a94b-c6975c1d76f6
SPL ID
d892628b-9528-4e28-8acc-906ad02abfd5
Version
20
Effective date
2026-09-28
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:42
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Neonatal Hypoglycemia : Closely monitor blood glucose concentration to ensure adequate glycemic control. ( 5.1 ) Hypersensitivity Reactions : Monitor for signs and symptoms and discontinue infusion immediately if reaction occurs. ( 5.2 ) Hyperglycemia and Hyperosmolar Hyperglycemic State : Use with caution in patients with known subclinical or overt diabetes mellitus. ( 5.3 ) Hyponatremia, Hypokalemia, Hypernatremia and Hyperchloremia : Avoid in patients with or at risk for hypo-/hypernatremia and hypokalemia. If use cannot be avoided, monitor serum sodium and potassium concentrations. ( 5.4 , 5.5 , 5.6 ) Fluid Overload : Avoid in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor daily fluid balance and electrolyte concentrations and acid-base balance, as needed and especially during prolonged use. ( 5.7 ) Phlebitis and Thrombosis : Remove catheter as soon as possible if thrombophlebitis develops. ( 5.8 ) Refeeding Syndrome : Monitor severely undernourished patients and slowly increase nutrient intake. ( 5.9 ) 5.1 Neonatal Hypoglycemia Neonates, especially preterm neonates with low birth weight, are at increased risk of developing hypoglycemia. Closely monitor blood glucose concentration during treatment with Dextrose and Sodium Chloride Injection to ensure adequate glycemic control in order to avoid potential long-term adverse effects. 5.2 Hypersensitivity Reactions Hypersensitivity and infusion reactions, including anaphylaxis, have been reported with Dextrose and Sodium Chloride Injection [see Adverse Reactions ( 6 )] . Stop administration of Dextrose and Sodium Chloride Injection immediately if signs or symptoms of a hypersensitivity reaction develop. Initiate appropriate treatment as clinically indicated. 5.3 Hyperglycemia and Hyperosmolar Hyperglycemic State The use of Dextrose and Sodium Chloride Injection in patients with impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death. Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration and electrolyte losses [see Warnings and Precautions ( 5.3 , 5.4 , 5.5 ), Use in Specific Populations ( 8.4 )] . Patients with underlying central nervous system disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose concentrations and treat hyperglycemia to maintain concentrations within normal limits while administering Dextrose and Sodium Chloride Injection. Insulin may be administered or adjusted to maintain optimal blood glucose concentrations during Dextrose and Sodium Chloride Injection administration. 5.4 Hyponatremia Dextrose and Sodium Chloride Injection may cause hyponatremia. The risk of hospital-acquired hyponatremia is increased in younger pediatric patients, geriatric patients, patients treated with diuretics, and patients with cardiac or pulmonary failure or with the syndrome of inappropriate antidiuretic hormone (SIADH) (e.g., postoperative patients, patients concomitantly treated with arginine vasopressin analogs or certain antiepileptic, psychotropic, and cytotoxic drugs) [see Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.4 )] . Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications such as osmotic demyelination syndrome (ODS) with risk of seizures and cerebral edema. To avoid complications, monitor serum sodium and chloride concentrations, fluid status, acid-based balance, and signs of neurologic complications. Avoid Dextrose and Sodium Chloride Injection in patients with or at risk for hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations, chloride concentrations, fluid status, acid-base balance, and neurologic status [see Warnings and Precautions ( 5.5 , 5.6 , 5.7 )] . 5.5 Hypokalemia Excessive administration of Dextrose and Sodium Chloride Injection may result in significant hypokalemia. Hypokalemic periodic paralysis, metabolic alkalosis, increased gastrointestinal losses (e.g. diarrhea, vomiting), prolonged low potassium diet, or primary hyperaldosteronism may increase the risk of hypokalemia. Avoid the administration of Dextrose and Sodium Chloride Injection in patients with or at risk of hypokalemia or taking medications that may increase the risk. If use cannot be avoided, monitor serum potassium levels. 5.6 Hypernatremia and Hyperchloremia Electrolyte imbalances such as hypernatremia and hyperchloremia, leading to metabolic acidosis may occur with solutions containing 0.9% sodium chloride. Conditions that may increase the risk of hypernatremia, fluid overload, and edema (central and peripheral), include patients with pre-eclampsia, primary hyperaldosteronism and secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, severe renal impairment, liver disease (including cirrhosis), and renal disease (including renal artery stenosis, nephrosclerosis). Medications such as corticosteroids or corticotropin, may increase the risk of sodium and fluid retention. Avoid solutions containing 0.9% sodium chloride in patients with or at risk for hypernatremia. If use cannot be avoided, monitor serum sodium concentrations. 5.7 Fluid Overload Depending on the volume and rate of infusion, the patient's underlying clinical condition and capability to metabolize dextrose, intravenous administration of Dextrose and Sodium Chloride Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Avoid Dextrose and Sodium Chloride Injection in patients with or at risk for fluid and/or solute overload. If use cannot be avoided, monitor fluid balance, electrolyte concentrations, and acid-base balance, especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration and/or free water load. 5.8 Phlebitis and Thrombosis The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis [see Dosage and Administration ( 2.1 )] . If thrombophlebitis develops, remove the catheter as soon as possible. 5.9 Refeeding Syndrome Refeeding severely undernourished patients may result in the refeeding syndrome that is characterized by the shift of potassium, phosphorus, and magnesium intracellularly as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intake.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS Neonatal Hypoglycemia [see Warnings and Precautions ( 5.1 )] Hypersensitivity [see Warnings and Precautions ( 5.2 )] Hyperglycemia and Hyperosmolar Hyperglycemic State [see Warnings and Precautions ( 5.3 )] Hyponatremia [see Warnings and Precautions ( 5.4 )] Hypokalemia [see Warnings and Precautions ( 5.5 )] Hypernatremia and Hyperchloremia [see Warnings and Precautions ( 5.6 )] Fluid Overload [see Warnings and Precautions ( 5.7 )] Phlebitis and Thrombosis [see Warnings and Precautions ( 5.8 )] Refeeding syndrome [see Warnings and Precautions ( 5.9 )] The following adverse reactions associated with the use of Dextrose and Sodium Chloride Injection were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Administration site conditions : Blister, erythema, extravasation, pain, phlebitis, vein damage, thrombosis. Immune system disorders : Anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritus, pyrexia, rash. Cardiovascular disorders : Cyanosis, volume overload. The most common adverse reactions include electrolyte imbalances, hyperglycemia, and hypervolemia, and injection site reactions. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-833-425-1464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . ­

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.